EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts

Yan Guo, Yanglei Cheng, Hai Li, Hongyu Guan, Haipeng Xiao, Yanbing Li

Investigative Opthalmology & Visual Science · 2023-06-16 · 64 (7) · 28

DOI: 10.1167/iovs.64.7.28 ↗

At a glance

Journal article in Investigative Opthalmology & Visual Science, published on 2023-06-16. Written by Yan Guo and 5 co-authors. Institution: Department of Endocrinology and Diabetes Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Graves Ophthalmopathy, Antimalarials, Artemisinins. Cited 11 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

Thyroid eye disease (TED) causes cosmetic defect and even threatens eyesight due to tissue remodeling in which orbital fibroblast (OF) plays a central role mainly by differentiating into adipocytes. Repurposing old drugs to novel applications is of particular interest. Here, we aimed to evaluate the effects of the antimalarials artemisinin (ARS) and the derivatives on the OFs isolated from patients with TED and their counterparts.

Methods

OFs isolated from patients with TED or their counterparts were cultured and passaged in proliferation medium (PM) and stimulated by differentiation medium (DM) for adipogenesis. OFs were treated with or without ARS, dihydroartemisinin (DHA), and artesunate (ART) at different concentrations, before being examined in vitro. CCK-8 were used to assess cellular viability. Cell proliferation was determined by EdU incorporation and flow cytometry. Lipid accumulation within the cells was evaluated by Oil Red O staining. Hyaluronan production was determined by ELISA. RNAseq, qPCR, and Western blot analysis were performed to illustrate the underlying mechanisms.

Results

ARSs dose-dependently interfered with lipid accumulation of TED-OFs, rather than non-TED-OFs. Meanwhile, the expression of key adipogenic markers, such as PLIN1, PPARG, FABP4, and CEBPA, was suppressed. During adipogenesis as being cultivated in DM, instead of PM, ARSs also inhibited cell cycle, hyaluronan production and the expression of hyaluronan synthase 2 (HAS2) in a concentration-dependent manner. Mechanically, the favorable effects were potentially mediated by the repression of IGF1R-PI3K-AKT signaling by dampening IGF1R expression.

Conclusions

Collectedly, our data evidenced that the conventional antimalarials ARSs were potentially therapeutic for TED.

Subjects

MeSH terms (MEDLINE)

Graves OphthalmopathyAntimalarialsArtemisininsHumansAdipogenesisHyaluronic AcidPhosphatidylinositol 3-KinasesFibroblastsLipidsCells, Cultured

Substances

Hyaluronic AcidAntimalarialsPhosphatidylinositol 3-KinasesArtemisininsLipids

Authors and institutions

  • Department of Endocrinology and Diabetes Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Cite

APA

Guo, Y., Cheng, Y., Li, H., Guan, H., Xiao, H., & Li, Y. (2023). The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts. Investigative Opthalmology & Visual Science, 64(7), 28. https://doi.org/10.1167/iovs.64.7.28

Vancouver

Guo Y, Cheng Y, Li H, Guan H, Xiao H, Li Y. The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts. Investigative Opthalmology & Visual Science. 2023;64(7):28. doi:10.1167/iovs.64.7.28

BibTeX
@article{Guo2023,
  author = {Guo, Yan and Cheng, Yanglei and Li, Hai and Guan, Hongyu and Xiao, Haipeng and Li, Yanbing},
  title = {The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2023},
  volume = {64},
  number = {7},
  pages = {28},
  doi = {10.1167/iovs.64.7.28}
}
Start for free →